Scarica l'app Stockscreener
70.82
0.21%
-0.15
Dopo l'orario di chiusura:
70.79
-0.03
-0.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CVS Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$70.97
Aprire:
$71.01
Volume 24 ore:
4.98M
Relative Volume:
0.65
Capitalizzazione di mercato:
$89.82B
Reddito:
$386.46B
Utile/perdita netta:
$4.49B
Rapporto P/E:
19.78
EPS:
3.58
Flusso di cassa netto:
$4.78B
1 W Prestazione:
+7.47%
1M Prestazione:
+14.30%
6M Prestazione:
+8.80%
1 anno Prestazione:
+20.24%
Intervallo 1D:
$70.65
$71.36
Intervallo di 1 settimana:
$66.24
$71.36
Portata 52W:
$43.56
$72.51
Cvs Health Corp Stock (CVS) Company Profile
Nome
Cvs Health Corp
Settore
Industria
Telefono
(401) 765-1500
Indirizzo
ONE CVS DR., WOONSOCKET
Confronta CVS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CVS
Cvs Health Corp
|
70.82 | 89.00B | 386.46B | 4.49B | 4.78B | 3.58 |
|
UNH
Unitedhealth Group Inc
|
299.84 | 279.39B | 422.82B | 22.09B | 25.27B | 23.08 |
|
CI
Cigna Group
|
304.57 | 79.63B | 261.22B | 5.40B | 3.94B | 18.32 |
|
ELV
Elevance Health Inc
|
310.00 | 69.65B | 189.25B | 5.35B | 5.34B | 23.50 |
|
HUM
Humana Inc
|
290.00 | 34.54B | 123.11B | 1.58B | 2.44B | 13.03 |
Cvs Health Corp Stock (CVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-14 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2025-02-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-02-12 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-01-30 | Aggiornamento | Edward Jones | Hold → Buy |
| 2024-12-03 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-11-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-10-10 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2024-10-04 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-05-30 | Iniziato | Robert W. Baird | Neutral |
| 2024-05-07 | Downgrade | TD Cowen | Buy → Hold |
| 2024-05-02 | Downgrade | UBS | Buy → Neutral |
| 2024-05-01 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-05-01 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-06 | Iniziato | Barclays | Equal Weight |
| 2024-02-26 | Iniziato | Leerink Partners | Outperform |
| 2023-12-22 | Iniziato | HSBC Securities | Buy |
| 2023-09-19 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-09-12 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-08-18 | Downgrade | Edward Jones | Buy → Hold |
| 2023-05-26 | Iniziato | Piper Sandler | Overweight |
| 2023-04-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-11-23 | Ripresa | Morgan Stanley | Overweight |
| 2022-06-17 | Iniziato | Loop Capital | Buy |
| 2022-05-27 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2022-03-29 | Downgrade | Deutsche Bank | Buy → Hold |
| 2022-02-11 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-12-14 | Iniziato | Goldman | Buy |
| 2021-12-01 | Iniziato | Seaport Research Partners | Buy |
| 2021-05-19 | Iniziato | Wells Fargo | Equal Weight |
| 2021-03-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-01-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-09-17 | Iniziato | Piper Sandler | Overweight |
| 2020-07-01 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-05-14 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-09-27 | Ripresa | RBC Capital Mkts | Outperform |
| 2019-09-12 | Iniziato | Deutsche Bank | Buy |
| 2019-06-05 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2019-04-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-04-18 | Iniziato | Guggenheim | Buy |
| 2019-04-15 | Downgrade | Oppenheimer | Outperform → Perform |
| 2019-04-10 | Reiterato | BofA/Merrill | Buy |
| 2019-03-13 | Iniziato | Bernstein | Outperform |
| 2019-02-20 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2019-01-17 | Iniziato | UBS | Buy |
| 2018-12-18 | Iniziato | Barclays | Overweight |
| 2018-11-29 | Ripresa | Goldman | Neutral |
| 2018-11-28 | Iniziato | Evercore ISI | Outperform |
| 2018-10-26 | Ripresa | Wolfe Research | Peer Perform |
| 2018-07-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-02-27 | Ripresa | BofA/Merrill | Buy |
| 2018-02-13 | Reiterato | Citigroup | Neutral |
Mostra tutto
Cvs Health Corp Borsa (CVS) Ultime notizie
CVS Caremark ordered to pay $290M after Medicare fraud scheme exposed by former Aetna whistleblower - Fox Business
CVS Settles UCLA Professor’s Drug Tool Trademark, Copyright Suit - Bloomberg Law News
CVS not entitled to insurance coverage for opioid litigation costs, Delaware Supreme Court rules - Providence Business News
CVS unit must pay $290 million in drug whistleblower lawsuit, judge rules - Reuters
CVS Opioid Insurance Loss Hits Companies Fighting Nuisance Suits - Bloomberg Law News
CVS PBM Overbilling Judgment Trebled To $289M - Law360
CVS Unit Must Pay $290 Million in Drug Whistleblower Lawsuit, Judge Rules - U.S. News & World Report
CVS Caremark Ordered to Pay $290 Million in Drug Fraud Suit (2) - Bloomberg Law News
CVS Health (NYSE:CVS) Upgraded to Strong-Buy at Baird R W - MarketBeat
Delaware court: CVS, not insurers, must pay opioid litigation costs - The Business Journals
CVS Health completes $4 billion debt offering, sets stage for major capital investment program - The Business Journals
Jefferies reiterates Buy rating on CVS Health stock, maintains $80 price target - Investing.com
CVS Health Stock Upgraded to Buy by UBS, Target Price Raised 13% - AInvest
CVS insurance policies don't provide opioid coverage, top Delaware court rules - Reuters
CVS Health upgraded by UBS on strong execution, margin improvement - Proactive financial news
CVS cannot obtain AIG, Chubb opioid coverage, top Delaware court rules - Yahoo Finance
CVS cannot obtain AIG, Chubb opioid coverage, top Delaware court rules By Reuters - Investing.com
CVS shares are breaking out to the upside after a 3-year bear market cycle, according to the charts - CNBC
Berkshire's UnitedHealth Bet Highlights Long-Term Confidence Despite Depressed Earnings - Benzinga
AIG, Chubb Beat CVS in Delaware on Opioid Litigation Claims (2) - Bloomberg Law News
CVS Health Earns UBS Upgrade After Beating Growth Expectations - Finimize
CVS Health upgraded, Occidental downgraded: Wall Street's top analyst calls - Yahoo Finance
CVS Health sells $4B in notes - Hartford Business Journal
UBS upgrades CVS, says turnaround in health benefits business gaining traction - Yahoo Finance
This CVS Health Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
Investors Heavily Search CVS Health Corporation (CVS): Here is What You Need to Know - Yahoo Finance
CVS Health Corporation $CVS Stock Holdings Lowered by State of New Jersey Common Pension Fund D - MarketBeat
CVS Health’s SWOT analysis: strong HCB growth fuels optimistic stock outlook - Investing.com
Prudential PLC Sells 33,509 Shares of CVS Health Corporation (NYSE:CVS) - MarketBeat
CVS Health Corporation (NYSE:CVS) Shares Sold by Virtu Financial LLC - MarketBeat
Mitsubishi UFJ Asset Management UK Ltd. Takes $1.22 Million Position in CVS Health Corporation (NYSE:CVS) - MarketBeat
Gulf International Bank UK Ltd Decreases Stock Holdings in CVS Health Corporation (NYSE:CVS) - MarketBeat
CVS Health Corporation (CVS) Is “The Last Man Standing,” Says Jim Cramer - Yahoo Finance
The three-year loss for CVS Health (NYSE:CVS) shareholders likely driven by its shrinking earnings - Yahoo Finance
CVS Health Corporation $CVS is Brandywine Global Investment Management LLC's 8th Largest Position - MarketBeat
Nuveen LLC Invests $204.42 Million in CVS Health Corporation (NYSE:CVS) - MarketBeat
Westpac Banking Corp Has $992,000 Holdings in CVS Health Corporation (NYSE:CVS) - MarketBeat
CVS HEALTH CORPORATION (CVS) - MSN
CVS Health: Health Insurers Get Buffett's Stamp Of Approval (Rating Upgrade) (NYSE:CVS) - Seeking Alpha
Robert W. Baird Upgrades CVS Health (NYSE:CVS) to Outperform - MarketBeat
Costco Refuses To Stock Abortion Pill Mifepristone, Pointing To 'Low Demand' As Activist Groups Step Up Pressure On Retail GiantsCostco Wholesale (NASDAQ:COST), Albertsons Companies (NYSE:ACI) - Benzinga
How sensitive is CVS Health Corporation to inflationShare Buyback & Safe Entry Trade Reports - newsyoung.net
SouthState Corp Grows Stake in CVS Health Corporation (NYSE:CVS) - MarketBeat
Persistent Asset Partners Ltd Sells 4,538 Shares of CVS Health Corporation (NYSE:CVS) - MarketBeat
CVS Health Corporation (CVS) Announces Issuance of Senior Notes - GuruFocus
Omnicare closing Northern Kentucky pharmacy, laying off dozens - The Business Journals
CVS Health Surges 2.9%: Analyst Upgrade and Value-Based Care Success Ignite Momentum - AInvest
Larry Robbins' Strategic Moves: CVS Health Corp Sees a -6.25% Portfolio Impact - Yahoo Finance
National Pension Service Has $213.58 Million Stock Position in CVS Health Corporation (NYSE:CVS) - MarketBeat
Q2 Earnings Highlights: AMN Healthcare Services (NYSE:AMN) Vs The Rest Of The Healthcare Providers & Services Stocks - Yahoo Finance
Preventive care is key at CVS - Providence Business News
Cvs Health Corp Azioni (CVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cvs Health Corp Azioni (CVS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ROBBINS LARRY | Director |
May 02 '25 |
Sale |
67.86 |
2,276,068 |
154,444,758 |
9,670,731 |
| ROBBINS LARRY | Director |
May 05 '25 |
Sale |
67.41 |
1,323,932 |
89,249,945 |
8,346,799 |
| ROBBINS LARRY | Director |
May 06 '25 |
Sale |
66.67 |
150,000 |
10,000,710 |
8,196,799 |
| Shah Prem S | EVP and Group President |
Mar 17 '25 |
Option Exercise |
62.21 |
846 |
52,630 |
43,190 |
| Clark James David | SVP, Cont & Chief Acct Officer |
Mar 05 '25 |
Option Exercise |
62.21 |
7,513 |
467,384 |
15,907 |
| Clark James David | SVP, Cont & Chief Acct Officer |
Mar 05 '25 |
Sale |
66.35 |
7,513 |
498,488 |
8,394 |
0.81%
0.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):